Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Beyond the clinic: 'direct-to-consumer' genomic profiling services and pharmacogenomics.

Prainsack B, Vayena E.

Pharmacogenomics. 2013 Mar;14(4):403-12. doi: 10.2217/pgs.13.10. Review.

PMID:
23438887
2.

Drug target pharmacogenomics: an overview.

Johnson JA.

Am J Pharmacogenomics. 2001;1(4):271-81. Review.

PMID:
12083959
3.

An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.

Phillips KA, Veenstra D, Van Bebber S, Sakowski J.

Pharmacogenomics. 2003 May;4(3):231-9. Review.

4.

Pharmacogenetics and pharmacogenomics: development, science, and translation.

Weinshilboum RM, Wang L.

Annu Rev Genomics Hum Genet. 2006;7:223-45. Review.

PMID:
16948615
5.

Pharmacogenetics, pharmacogenomics and airway disease.

Hall IP.

Respir Res. 2002;3:10. Epub 2001 Nov 26. Review.

6.

HIV resistance testing in the USA--a model for the application of pharmacogenomics in the clinical setting.

Blum RA, Wylie N, England T, French C.

Pharmacogenomics. 2005 Mar;6(2):169-79. Review.

PMID:
15882135
8.

Rapid and cost-effective SNP detection method: application of SmartAmp2 to pharmacogenomics research.

Mitani Y, Lezhava A, Sakurai A, Horikawa A, Nagakura M, Hayashizaki Y, Ishikawa T.

Pharmacogenomics. 2009 Jul;10(7):1187-97. doi: 10.2217/pgs.09.39.

PMID:
19604094
9.

Pharmacogenetics and pharmacogenomics in the discovery and development of medicines.

Roses AD.

Novartis Found Symp. 2000;229:63-6; discussion 66-70. No abstract available.

PMID:
11084930
10.

The role of cost-effectiveness analysis in the era of pharmacogenomics.

Flowers CR, Veenstra D.

Pharmacoeconomics. 2004;22(8):481-93. Review.

PMID:
15217305
11.

Systematic review of pharmacoeconomic studies of pharmacogenomic tests.

Beaulieu M, de Denus S, Lachaine J.

Pharmacogenomics. 2010 Nov;11(11):1573-90. doi: 10.2217/pgs.10.145. Review.

PMID:
21121811
12.

Pharmacogenomics: a systems approach.

Wang L.

Wiley Interdiscip Rev Syst Biol Med. 2010 Jan-Feb;2(1):3-22. doi: 10.1002/wsbm.42. Review.

13.

Unleashing the power of preemptive pharmacogenomics.

O'Donnell PH.

Clin Adv Hematol Oncol. 2014 Oct;12(10):695-7. No abstract available.

PMID:
25658895
14.

Pathology practice and pharmacogenomics.

Trent RJ.

Pharmacogenomics. 2010 Jan;11(1):105-11. doi: 10.2217/pgs.09.150. Review.

PMID:
20017676
15.

Pharmacogenomics: the promise of personalized medicine for CNS disorders.

de Leon J.

Neuropsychopharmacology. 2009 Jan;34(1):159-72. doi: 10.1038/npp.2008.147. Epub 2008 Sep 17. Review.

16.

Direct-to-consumer genome testing: opportunities for pharmacogenomics research?

Prainsack B, Wolinsky H.

Pharmacogenomics. 2010 May;11(5):651-5. doi: 10.2217/pgs.10.33. Review.

17.

A pharmacogenomics primer.

Court MH.

J Clin Pharmacol. 2007 Sep;47(9):1087-103. Epub 2007 Jul 30. Review.

PMID:
17664254
18.

Role of genomics on the path to personalized medicine.

Tremblay J, Hamet P.

Metabolism. 2013 Jan;62 Suppl 1:S2-5. doi: 10.1016/j.metabol.2012.08.023. Epub 2012 Sep 25.

PMID:
23021037
19.

Ethical perspectives on pharmacogenomic profiling in the drug development process.

Issa AM.

Nat Rev Drug Discov. 2002 Apr;1(4):300-8. Review.

PMID:
12120281
20.

Translating pharmacogenomics: challenges on the road to the clinic.

Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, Guchelaar HJ.

PLoS Med. 2007 Aug;4(8):e209. Review.

Supplemental Content

Support Center